Litcius/Paper detail

Active-site molecular docking of nigellidine with nucleocapsid–NSP2–MPro of COVID-19 and to human IL1R–IL6R and strong antioxidant role of <i>Nigella sativa</i> in experimental rats

Smarajit Maiti, Amrita Banerjee, Aarifa Nazmeen, Mehak Kanwar, Shilpa Das

2020Journal of drug targeting45 citationsDOI

Abstract

Where nigellidine showed highest binding energy of -6.6 kcal/mol, ligand efficiency of -0.3 with COVID19 Nsp2 forming bonds with amino acid CYS240 present in binding pocket. Nigellidine showed strong interaction with main protease (BE: -6.38/LE: -0.29). Nigellidine showed affinity to IL1R (-6.23). The NS treated rat showed marked decline in ALP-SGPT-SGOT-malondialdehyde (MDA) than the basal levels. From the Western blot and activity analysis, it was observed that Nigellidine (sulphuryl group drug) showed no impact on phenol-catalysing ASTIV and steroid-catalysing oestrogen-sulphotransferase expressions and activities in liver tissue and thus has no influence in sulphation-mediated adverse metabolic processes. Conclusively, nigellidine has hepato-reno-protective/antioxidant-immunomodulatory/anti-inflammatory activities with inhibit potentials of COVID-19 proteins. Further validation is necessary.

Topics & Concepts

AutoDockDocking (animal)ChemistryProteaseBiochemistryThymoquinoneAntioxidantProtein Data Bank (RCSB PDB)In silicoNigella sativaEnzymeGlutathioneWestern blotPharmacologyBinding siteAmino acidHomology modelingPlasma protein bindingIn vitroGlycoproteinStructure–activity relationshipMolecular modelNigella sativa pharmacological applicationsDiverse Scientific Research StudiesAnimal Virus Infections Studies
Active-site molecular docking of nigellidine with nucleocapsid–NSP2–MPro of COVID-19 and to human IL1R–IL6R and strong antioxidant role of <i>Nigella sativa</i> in experimental rats | Litcius